Cardiome Enters Commercialization Agreement With Algorithm S.A.L. For BRINAVESS™ In Middle East And North Africa

    Cardiome Enters Commercialization Agreement With Algorithm S.A.L. For
                  BRINAVESS™ In Middle East And North Africa

PR Newswire

VANCOUVER, Oct. 21, 2013

NASDAQ: CRME TSX: COM

VANCOUVER, Oct. 21, 2013 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME /
TSX: COM) today announced that its subsidiary, Cardiome International AG, has
entered into an agreement with Algorithm S.A.L., headquartered in Beirut,
Lebanon, to sell and distribute BRINAVESS™ (vernakalant intravenous)
exclusively in certain Middle Eastern and North African countries. Under the
terms of the agreement, Algorithm has agreed to specific annual commercial
goals for BRINAVESS. Financial details of the agreement have not been
disclosed.

"We are pleased  to have  entered into this  commercialization agreement  with 
Algorithm, a  highly respected  company  with an  impressive track  record  in 
partnering with other pharma industry  leaders," said Karim Lalji,  Cardiome's 
Chief Commercial Officer. "We look forward to continuing the commercialization
of BRINAVESS  in  approved markets  and  leveraging Algorithm's  expertise  in 
gaining approvals in new ones."

"Algorithm is excited to be working with Cardiome to sell and distribute
BRINAVESS," said Nabil Ghorayeb, Human Health Lead, at Algorithm. "Our company
has a long and successful history in the cardiovascular market, and BRINAVESS
is an excellent addition to our product portfolio that will offer our
customers a treatment option for the rapid conversion of recent onset atrial
fibrillation."

The initial term of this commercial agreement begins November 1, 2013 for  the 
duration of  five  years and  is  renewable on  an  annual basis,  or  longer, 
thereafter. Countries covered by the agreement where Algorithm will be able to
commercialize  BRINAVESS  include:  Algeria;  Bahrain;  Egypt;  Iran;  Jordan; 
Kingdom of  Saudi  Arabia;  Kuwait;  Lebanon;  Libya;  Morocco;  Oman;  Qatar; 
Tunisia; and United Arab Emirates.

About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a biopharmaceutical company dedicated to the
discovery, development and commercialization of new therapies that will
improve the health of patients around the world. Cardiome has one marketed
product, BRINAVESS^TM (vernakalant IV), approved in Europe and other
territories for the rapid conversion of recent onset atrial fibrillation to
sinus rhythm in adults.

Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock
Exchange (COM). For more information, please visit our web site at
www.cardiome.com.

About Algorithm S.A.L.
Algorithm, a Lebanon-based pharmaceutical manufacturer, is actively present in
the Middle East and North Africa region and Cyprus. Algorithm is dedicated to
offering quality products, either  under license from reputable  international 
companies  or  developed  by  the  company's  product  development  team.  The 
portfolio consists of innovative products as well as differentiated  generics, 
focusing mainly on the following therapeutic areas: Cardiometabolic  Diseases, 
Neurology, Endocrinology,  Onco-Hematology, Uro-Gynecology,  and  Dermatology. 
For more information, visit www.algorithm-lb.com/en_Home.

Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 or
forward-looking information under applicable Canadian securities legislation
that may not be based on historical fact, including without limitation
statements containing the words "believe", "may", "plan", "will", "estimate",
"continue", "anticipate", "intend", "expect" and similar expressions.
Forward- looking statements may involve, but are not limited to, comments with
respect to our objectives and priorities for the remainder of 2013 and beyond,
our strategies or future actions, our targets, expectations for our financial
condition and the results of, or outlook for, our operations, research and
development and product and drug development. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors that may
cause the actual results, events or developments to be materially different
from any future results, events or developments expressed or implied by such
forward-looking statements. Many such known risks, uncertainties and other
factors are taken into account as part of our assumptions underlying these
forward-looking statements and include, among others, the following: general
economic and business conditions in the United States, Canada, Europe, and the
other regions in which we operate; market demand; technological changes that
could impact our existing products or our ability to develop and commercialize
future products; competition; existing governmental legislation and
regulations and changes in, or the failure to comply with, governmental
legislation and regulations; availability of financial reimbursement coverage
from governmental and third-party payers for products and related treatments;
adverse results or unexpected delays in pre-clinical and clinical product
development processes; adverse findings related to the safety and/or efficacy
of our products or products; decisions, and the timing of decisions, made by
health regulatory agencies regarding approval of our technology and products;
the requirement for substantial funding to expand commercialization
activities; and any other factors that may affect our performance. In
addition, our business is subject to certain operating risks that may cause
any results expressed or implied by the forward-looking statements in this
presentation to differ materially from our actual results. These operating
risks include: our ability to attract and retain qualified personnel; our
ability to successfully complete pre-clinical and clinical development of our
products; changes in our business strategy or development plans; intellectual
property matters, including the unenforceability or loss of patent protection
resulting from third-party challenges to our patents; market acceptance of our
technology and products; our ability to successfully manufacture, market and
sell our products; the availability of capital to finance our activities; and
any other factors described in detail in our filings with the Securities and
Exchange Commission available at www.sec.gov and the Canadian securities
regulatory authorities at www.sedar.com. Given these risks, uncertainties and
factors, you are cautioned not to place undue reliance on such forward-looking
statements and information, which are qualified in their entirety by this
cautionary statement. All forward-looking statements and information made
herein are based on our current expectations and we undertake no obligation to
revise or update such forward-looking statements and information to reflect
subsequent events or circumstances, except as required by law.

SOURCE Cardiome Pharma Corp.

Contact:

Cardiome Investor Relations
(604) 676-6993 or Toll Free: 1-800-330-9928
Email:ir@cardiome.com
 
Press spacebar to pause and continue. Press esc to stop.